Eval. of Sirolimus in Treatment of Bilateral Geographic Atrophy

评估。

• 批准号: 8938341
• 负责人: EMILY Y CHEW
• 金额: $ 13.09万
• 依托单位: NATIONAL EYE INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8938341
• 关键词: Affect; Age related macular degeneration; Area; Bilateral; Cells; Clinical Protocols; Drusen; Eye; Fundus photography; Image; Inflammation; Injection of therapeutic agent; Masks; Measures; Outcome; Participant; Patients; Pharmaceutical Preparations; Reading; Relative (related person); Retina; Safety; Sirolimus; Testing; Vision; base; digital; geographic atrophy; macula; prevent; primary outcome; secondary outcome

This study will determine if a drug called sirolimus is safe to give to people with geographic atrophy GA and if it can help preserve vision in patients. GA is an advanced form of dry age-related macular degeneration (AMD). AMD affects the macula, the central part of the retina needed for sharp, clear vision. There are two types of AMD, wet and dry. In dry AMD, cells in the macula die.GA may at least partly be caused by inflammation. Sirolimus helps prevent inflammation and therefore may help treat GA.

这项研究将确定一种名为西罗莫司的药物是否可以安全用于地理萎缩性GA患者，以及它是否有助于保护患者的视力。GA是干性老年性黄斑变性（AMD）的一种晚期形式。老年性黄斑变性影响黄斑，黄斑是视网膜的中心部分，是保持敏锐、清晰视力所必需的。AMD有两种类型，湿性和干性。在干性黄斑变性中，黄斑细胞死亡。GA至少部分是由炎症引起的。西罗莫司有助于预防炎症，因此可能有助于治疗GA。